CA
NZ
UK
AU
IND
US
…
Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026. The company was incorporated in 2002 and is based in Nedlands, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Neuroscientific Biopharmaceuticals Ltd is an Australian biotechnology company listed on the ASX that appears positioned in the neuroscience therapeutics sector, though public disclosures about its programs are limited. Long-term growth drivers may include clinical development progress, successful regulatory outcomes and commercial partnerships or licensing that could advance its pipeline and address unmet needs in neurological disorders, which may benefit investors seeking exposure to neuroscience drug development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -5.10M | -1.85M | -1.89M | -1.07M | -10.44M |
| Net income | -4.69M | -1.85M | 0.32M | -1.07M | -10.50M |
| Selling general administrative | - | 0.63M | 0.65M | 1.77M | 2.73M |
| Selling and marketing expenses | - | 0.08M | 0.08M | - | - |
| Gross profit | -1.38M | -0.09M | -0.09M | - | - |
| Reconciled depreciation | - | 0.09M | 0.09M | 0.06M | 0.06M |
| Ebit | -5.11M | -2.01M | -1.89M | -1.06M | -10.50M |
| Ebitda | -3.72M | -1.92M | -1.80M | -1.01M | -10.44M |
| Depreciation and amortization | 1.38M | 0.09M | 0.09M | 0.06M | 0.06M |
| Operating income | -5.11M | -1.92M | -2.06M | -1.06M | -10.50M |
| Other operating expenses | 5.11M | 1.92M | 2.06M | 6.12M | 10.50M |
| Interest expense | 0.00M | 0.00M | 0.01M | 0.00M | 0.07M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.17M | 0.18M | 0.00M | 0.07M |
| Net interest income | - | 0.16M | 0.17M | 0.10M | 0.07M |
| Income tax expense | -0.40M | - | -2.21M | 4.96M | 0.07M |
| Total revenue | - | 0.17M | 2.21M | 5.06M | 0.07M |
| Total operating expenses | 3.72M | 1.92M | 1.97M | 6.12M | 10.50M |
| Cost of revenue | 1.38M | 0.00M | 0.09M | - | - |
| Total other income expense net | 0.01M | 0.16M | 0.17M | 4.95M | 0.07M |
| Net income from continuing ops | - | -1.85M | 0.32M | -1.07M | -10.44M |
| Net income applicable to common shares | - | -1.85M | 0.32M | -1.07M | -10.44M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 15.18M | 16.96M | 5.44M | 5.29M | 7.74M |
| Intangible assets | 10.27M | 9.57M | - | 0.27M | 0.32M |
| Other current assets | 0.04M | - | 0.04M | 0.05M | 0.06M |
| Total liab | 0.37M | 0.15M | 0.09M | 0.60M | 2.22M |
| Total stockholder equity | 14.81M | 16.81M | 5.35M | 4.69M | 5.52M |
| Other current liab | 0.02M | - | 0.00M | 0.01M | 0.05M |
| Common stock | 38.81M | - | 25.52M | 25.27M | 25.27M |
| Capital stock | - | 34.26M | - | 25.27M | 25.27M |
| Retained earnings | -26.71M | -23.28M | -22.04M | -22.99M | -22.60M |
| Cash | 2.63M | 7.27M | 4.95M | 4.91M | 7.22M |
| Cash and equivalents | - | - | - | - | 7.22M |
| Total current liabilities | 0.34M | 0.15M | 0.09M | 0.60M | 2.22M |
| Net debt | -2.54M | - | -4.95M | -4.91M | -7.22M |
| Short term debt | 0.05M | - | - | - | 0.00M |
| Short long term debt total | 0.09M | - | - | - | - |
| Other stockholder equity | - | - | - | 2.41M | 2.84M |
| Property plant equipment | - | - | - | 0.01M | 0.02M |
| Total current assets | 4.80M | 7.40M | 5.04M | 5.01M | 7.40M |
| Net tangible assets | - | - | - | 4.42M | 5.20M |
| Short term investments | 2.00M | - | - | - | - |
| Net receivables | 0.13M | 0.07M | 0.05M | 0.04M | 0.12M |
| Accounts payable | 0.27M | 0.15M | 0.08M | 0.59M | 2.17M |
| Accumulated other comprehensive income | 2.71M | - | 1.87M | 2.41M | 2.84M |
| Non currrent assets other | - | - | 0.39M | -0.28M | -0.34M |
| Non current assets total | 10.39M | 9.57M | 0.39M | 0.28M | 0.34M |
| Long term debt total | - | - | - | - | 0.00M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -0.04M | -0.00M | - | -0.00M |
| Change to liabilities | - | - | - | -1.58M | 1.99M |
| Total cashflows from investing activities | -2.00M | -0.04M | -0.00M | 0.00M | -0.00M |
| Total cash from financing activities | -0.03M | 3.29M | 0.00M | 0.00M | 0.00M |
| Change to operating activities | - | - | - | -0.03M | 0.16M |
| Net income | -4.69M | -1.85M | 0.32M | -1.07M | -10.44M |
| Change in cash | -4.64M | 2.31M | 0.04M | -2.30M | -6.95M |
| Begin period cash flow | 7.27M | 4.95M | 4.91M | 7.22M | 14.16M |
| End period cash flow | 2.63M | 7.27M | 4.95M | 4.91M | 7.22M |
| Total cash from operating activities | -2.61M | -0.94M | 0.04M | -2.30M | -6.94M |
| Issuance of capital stock | - | 3.50M | - | - | - |
| Depreciation | 1.38M | 0.09M | 0.09M | 0.06M | 0.06M |
| Change to inventory | - | - | - | 1.61M | -2.15M |
| Change to account receivables | -0.03M | -0.04M | -0.01M | 0.08M | -0.07M |
| Sale purchase of stock | - | -0.21M | - | 0.00M | 0.00M |
| Other cashflows from financing activities | -0.02M | - | -0.00M | - | -0.00M |
| Change to netincome | - | - | - | 0.24M | 1.35M |
| Capital expenditures | 2.61M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.07M | -0.04M | -0.50M | -1.54M | 2.08M |
| Stock based compensation | - | 0.80M | - | 0.24M | 1.35M |
| Other non cash items | 0.63M | 0.05M | 0.55M | 1.86M | -0.44M |
| Free cash flow | - | -0.94M | 0.04M | -2.30M | -6.95M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NSB Neuroscientific Biopharmaceuticals Ltd |
-0.01 24.07% |
0.04 | - | - | 52.26 | 1.18 | 39.23 |
| CSL CSL Ltd |
2.86 1.42% |
204.54 | - | 22.57 | 6.15 | 4.48 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.32 2.28% |
13.70 | 93.87 | 166.67 | 5.37 | 6.37 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
-0.30 1.25% |
23.66 | 154.93 | 36.36 | 42.38 | 7.52 | 160.40 |
| MSB Mesoblast Ltd |
-0.07 3.69% |
1.96 | - | 454.55 | 23.43 | 3.36 | -9.86 |
Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026. The company was incorporated in 2002 and is based in Nedlands, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC | Interim CEO & CHairman | 1959 |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Sec. | NA |
| Dougal Thring | Chief Operating Officer | NA |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | NA |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | NA |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | NA |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | NA |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | NA |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | NA |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.29%
Communication Services
+0.51%
Consumer Cyclical
-0.08%
Consumer Defensive
-0.14%
Energy
+1.08%
Financial Services
+0.14%
Financials
-0.06%
Healthcare
+0.51%
Industrials
+0.47%
Real Estate
-0.23%
Technology
+2.03%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...